Literature DB >> 9840015

Clinical studies of 13C-urea breath test in Japan.

M Kato1, M Asaka, S Ohara, T Toyota.   

Abstract

The urea breath test (UBT) using isotope carbon is a non-invasive method for diagnosing H. pylori infection. In Japan, only 13C-UBT using a stable isotope is available, since the clinical use of radioactive isotope 14C-compounds is prohibited. Since there is no worldwide standard protocol for the 13C-UBT, it is therefore important to standardize this test to obtain a cheap, easy, reproducible method. Factors affecting the outcome of 13C-UBT values include sampling times and frequency, the amount of 13C-urea, the cut-off value, the avoidance of oral urease activity, and changes in gastric emptying times and 13C-urea distribution. Mouth rinsing reduces false-positive results due to oral urease activity, particularly within 20 min after ingestion of 13C-urea. A Japanese multicenter trial has shown that the diagnostic utility of 13C-UBT is superb, with the cut-off value 2.5/1000 in 20-min samples after ingestion of 100 mg 13C-urea. The 13C-UBT is a very useful method for diagnosing H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9840015

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  9 in total

1.  Clinical significance of oral urease in diagnosis of Helicobacter pylori infection by [13C]urea breath test.

Authors:  N J Peng; K H Lai; R S Liu; S C Lee; D G Tsay; C C Lo; H H Tseng; W K Huang; G H Lo; P I Hsu
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

2.  Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Hitoshi Tsugawa; Seiichiro Fukuhara; Sawako Miyoshi; Kenro Hirata; Takashi Seino; Misako Matsushita; Toshihiro Nishizawa; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2015-11-13       Impact factor: 4.623

3.  Changes in gastric mucosal patterns seen by magnifying NBI during H. pylori eradication.

Authors:  Masaaki Okubo; Tomomitsu Tahara; Tomoyuki Shibata; Masakatsu Nakamura; Daisuke Yoshioka; Yoshiteru Maeda; Joh Yonemura; Takamitsu Ishizuka; Tomiyasu Arisawa; Ichiro Hirata
Journal:  J Gastroenterol       Date:  2010-10-22       Impact factor: 7.527

4.  Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database.

Authors:  Hisato Deguchi; Akihito Uda; Kazunari Murakami
Journal:  Digestion       Date:  2019-06-19       Impact factor: 3.216

5.  An optimized 13C-urea breath test for the diagnosis of H pylori infection.

Authors:  Germán Campuzano-Maya
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

6.  Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2017-01-19       Impact factor: 4.623

7.  Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients.

Authors:  Hideki Mori; Hidekazu Suzuki; Fumio Omata; Tatsuhiro Masaoka; Daisuke Asaoka; Kohei Kawakami; Shigeaki Mizuno; Naoto Kurihara; Akihito Nagahara; Nobuhiro Sakaki; Masayoshi Ito; Yo Kawamura; Masayuki Suzuki; Yuji Shimada; Hitoshi Sasaki; Takeshi Matsuhisa; Akira Torii; Toshihiro Nishizawa; Tetsuya Mine; Toshifumi Ohkusa; Takashi Kawai; Kengo Tokunaga; Shin'ichi Takahashi
Journal:  Therap Adv Gastroenterol       Date:  2019-07-04       Impact factor: 4.409

8.  Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.

Authors:  Kazumi Inokuchi; Hideki Mori; Juntaro Matsuzaki; Kenro Hirata; Yosuke Harada; Yoshimasa Saito; Hidekazu Suzuki; Takanori Kanai; Tatsuhiro Masaoka
Journal:  Helicobacter       Date:  2022-05-29       Impact factor: 5.182

9.  Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.

Authors:  Naohito Shirai; Mitsushige Sugimoto; Chise Kodaira; Masafumi Nishino; Mutsuhiro Ikuma; Masayoshi Kajimura; Kyoichi Ohashi; Takashi Ishizaki; Akira Hishida; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2007-06-13       Impact factor: 3.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.